BLTE Earnings Date & History
Belite Bio Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:17 PM ET
Belite Bio Inc
Pharmaceuticals
- Next earnings date
- Monday, November 9, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.85
- Revenue estimate
- $0
BLTE earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, May 20, 2026 | Q1 2026 | $-0.65 | $-0.68 | -4.9% | $0 |
| Monday, March 2, 2026 | Q4 2025 | $-0.56 | $-0.70 | -25.6% | $0 |
| Monday, November 10, 2025 | Q3 2025 | $-0.50 | $-0.65 | -30.7% | $0 |
| Monday, August 11, 2025 | Q2 2025 | $-0.43 | $-0.50 | -17.4% | $0 |
What the market is watching in BLTE's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next BLTE earnings date?
- Belite Bio Inc is scheduled to report on Monday, November 9, 2026 (Time TBD). Dates can change until the company confirms them.
- Does BLTE report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for BLTE?
- Consensus EPS for the upcoming quarter is $-0.85, on revenue of $0.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
BLTE earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.